Clinical evaluation of recombinant human bone morphogenetic protein-2
- PMID: 11937870
- DOI: 10.1097/00003086-200202000-00011
Clinical evaluation of recombinant human bone morphogenetic protein-2
Abstract
Recombinant human bone morphogenetic protein-2 is an osteoinductive protein that plays a pivotal role in bone growth and regeneration. Several hundred studies were conducted in the past 7 years in numerous animal models to establish unequivocally the efficacy, safety, mechanism of action, pharmacokinetics, and surgical handling properties of recombinant human bone morphogenetic protein-2, building a solid foundation for clinical development programs. Pilot clinical trials have shown the feasibility and safety of recombinant human bone morphogenetic protein-2 treatment, and defined the effective dose for its use in open long bone fractures and for augmentation or preservation of the alveolar bone in the dental ridge. Prospective observational clinical studies helped define clinical efficacy end points, identify significant variables, and estimate appropriate population sample size for pivotal clinical trials. Pivotal clinical trials of recombinant human bone morphogenetic protein-2 are underway in patients with open tibial shaft fractures and in patients with a deficiency of the alveolar ridge.
Similar articles
-
Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies.J Bone Joint Surg Am. 2006 Jun;88(6):1258-65. doi: 10.2106/JBJS.E.00499. J Bone Joint Surg Am. 2006. PMID: 16757759 Clinical Trial.
-
Recombinant human bone morphogenic protein-2 in fracture care.J Orthop Trauma. 2005 Nov-Dec;19(10 Suppl):S23-5. doi: 10.1097/00005131-200511101-00007. J Orthop Trauma. 2005. PMID: 16479219 Clinical Trial.
-
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients.J Bone Joint Surg Am. 2002 Dec;84(12):2123-34. doi: 10.2106/00004623-200212000-00001. J Bone Joint Surg Am. 2002. PMID: 12473698 Clinical Trial.
-
Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft?Acta Orthop Belg. 2005 Apr;71(2):133-48. Acta Orthop Belg. 2005. PMID: 16152845 Review.
-
A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft).Int Orthop. 2007 Dec;31(6):729-34. doi: 10.1007/s00264-007-0418-6. Epub 2007 Jul 17. Int Orthop. 2007. PMID: 17639384 Free PMC article. Review.
Cited by
-
Targeted gene-and-host progenitor cell therapy for nonunion bone fracture repair.Mol Ther. 2011 Jan;19(1):53-9. doi: 10.1038/mt.2010.190. Epub 2010 Sep 21. Mol Ther. 2011. PMID: 20859259 Free PMC article.
-
The effect of NELL1 and bone morphogenetic protein-2 on calvarial bone regeneration.J Oral Maxillofac Surg. 2010 Feb;68(2):300-8. doi: 10.1016/j.joms.2009.03.066. J Oral Maxillofac Surg. 2010. PMID: 20116699 Free PMC article.
-
Efficacy of the Combination of rhBMP-2 with Bone Marrow Aspirate Concentrate in Mandibular Defect Reconstruction after a Pindborg Tumor Resection.Case Rep Dent. 2020 Mar 18;2020:8281741. doi: 10.1155/2020/8281741. eCollection 2020. Case Rep Dent. 2020. PMID: 32257455 Free PMC article.
-
Interventions for replacing missing teeth: horizontal and vertical bone augmentation techniques for dental implant treatment.Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD003607. doi: 10.1002/14651858.CD003607.pub4. Cochrane Database Syst Rev. 2009. PMID: 19821311 Free PMC article. Review.
-
A study of the role of nell-1 gene modified goat bone marrow stromal cells in promoting new bone formation.Mol Ther. 2007 Oct;15(10):1872-80. doi: 10.1038/sj.mt.6300270. Epub 2007 Jul 24. Mol Ther. 2007. PMID: 17653100 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous